Copyright Reports & Markets. All rights reserved.

Global LATAM Adalimumab Market Professional Survey Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Industry Overview of LATAM Adalimumab

      • 1.1 Definition of LATAM Adalimumab
      • 1.2 LATAM Adalimumab Segment by Type
        • 1.2.1 Global LATAM Adalimumab Production Growth Rate Comparison by Types (2014-2025)
        • 1.2.2 Oral Type
        • 1.2.3 Injection Type
      • 1.3 LATAM Adalimumab Segment by Applications
        • 1.3.1 Global LATAM Adalimumab Consumption Comparison by Applications (2014-2025)
        • 1.3.2 Rheumatoid Arthritis
        • 1.3.3 Psoriasis
        • 1.3.4 Crohn’s Disease
        • 1.3.5 Ulcerative Colitis
        • 1.3.6 Others
      • 1.4 Global LATAM Adalimumab Overall Market
        • 1.4.1 Global LATAM Adalimumab Revenue (2014-2025)
        • 1.4.2 Global LATAM Adalimumab Production (2014-2025)
        • 1.4.3 North America LATAM Adalimumab Status and Prospect (2014-2025)
        • 1.4.4 Europe LATAM Adalimumab Status and Prospect (2014-2025)
        • 1.4.5 China LATAM Adalimumab Status and Prospect (2014-2025)
        • 1.4.6 Japan LATAM Adalimumab Status and Prospect (2014-2025)
        • 1.4.7 Southeast Asia LATAM Adalimumab Status and Prospect (2014-2025)
        • 1.4.8 India LATAM Adalimumab Status and Prospect (2014-2025)

      2 Manufacturing Cost Structure Analysis

      • 2.1 Raw Material and Suppliers
      • 2.2 Manufacturing Cost Structure Analysis of LATAM Adalimumab
      • 2.3 Manufacturing Process Analysis of LATAM Adalimumab
      • 2.4 Industry Chain Structure of LATAM Adalimumab

      3 Development and Manufacturing Plants Analysis of LATAM Adalimumab

      • 3.1 Capacity and Commercial Production Date
      • 3.2 Global LATAM Adalimumab Manufacturing Plants Distribution
      • 3.3 Major Manufacturers Technology Source and Market Position of LATAM Adalimumab
      • 3.4 Recent Development and Expansion Plans

      4 Key Figures of Major Manufacturers

      • 4.1 LATAM Adalimumab Production and Capacity Analysis
      • 4.2 LATAM Adalimumab Revenue Analysis
      • 4.3 LATAM Adalimumab Price Analysis
      • 4.4 Market Concentration Degree

      5 LATAM Adalimumab Regional Market Analysis

      • 5.1 LATAM Adalimumab Production by Regions
        • 5.1.1 Global LATAM Adalimumab Production by Regions
        • 5.1.2 Global LATAM Adalimumab Revenue by Regions
      • 5.2 LATAM Adalimumab Consumption by Regions
      • 5.3 North America LATAM Adalimumab Market Analysis
        • 5.3.1 North America LATAM Adalimumab Production
        • 5.3.2 North America LATAM Adalimumab Revenue
        • 5.3.3 Key Manufacturers in North America
        • 5.3.4 North America LATAM Adalimumab Import and Export
      • 5.4 Europe LATAM Adalimumab Market Analysis
        • 5.4.1 Europe LATAM Adalimumab Production
        • 5.4.2 Europe LATAM Adalimumab Revenue
        • 5.4.3 Key Manufacturers in Europe
        • 5.4.4 Europe LATAM Adalimumab Import and Export
      • 5.5 China LATAM Adalimumab Market Analysis
        • 5.5.1 China LATAM Adalimumab Production
        • 5.5.2 China LATAM Adalimumab Revenue
        • 5.5.3 Key Manufacturers in China
        • 5.5.4 China LATAM Adalimumab Import and Export
      • 5.6 Japan LATAM Adalimumab Market Analysis
        • 5.6.1 Japan LATAM Adalimumab Production
        • 5.6.2 Japan LATAM Adalimumab Revenue
        • 5.6.3 Key Manufacturers in Japan
        • 5.6.4 Japan LATAM Adalimumab Import and Export
      • 5.7 Southeast Asia LATAM Adalimumab Market Analysis
        • 5.7.1 Southeast Asia LATAM Adalimumab Production
        • 5.7.2 Southeast Asia LATAM Adalimumab Revenue
        • 5.7.3 Key Manufacturers in Southeast Asia
        • 5.7.4 Southeast Asia LATAM Adalimumab Import and Export
      • 5.8 India LATAM Adalimumab Market Analysis
        • 5.8.1 India LATAM Adalimumab Production
        • 5.8.2 India LATAM Adalimumab Revenue
        • 5.8.3 Key Manufacturers in India
        • 5.8.4 India LATAM Adalimumab Import and Export

      6 LATAM Adalimumab Segment Market Analysis (by Type)

      • 6.1 Global LATAM Adalimumab Production by Type
      • 6.2 Global LATAM Adalimumab Revenue by Type
      • 6.3 LATAM Adalimumab Price by Type

      7 LATAM Adalimumab Segment Market Analysis (by Application)

      • 7.1 Global LATAM Adalimumab Consumption by Application
      • 7.2 Global LATAM Adalimumab Consumption Market Share by Application (2014-2019)

      8 LATAM Adalimumab Major Manufacturers Analysis

      • 8.1 AbbVie, Inc.
        • 8.1.1 AbbVie, Inc. LATAM Adalimumab Production Sites and Area Served
        • 8.1.2 AbbVie, Inc. Product Introduction, Application and Specification
        • 8.1.3 AbbVie, Inc. LATAM Adalimumab Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.1.4 Main Business and Markets Served
      • 8.2 Amgen, Inc.
        • 8.2.1 Amgen, Inc. LATAM Adalimumab Production Sites and Area Served
        • 8.2.2 Amgen, Inc. Product Introduction, Application and Specification
        • 8.2.3 Amgen, Inc. LATAM Adalimumab Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.2.4 Main Business and Markets Served
      • 8.3 Boehringer Ingelheim GmbH
        • 8.3.1 Boehringer Ingelheim GmbH LATAM Adalimumab Production Sites and Area Served
        • 8.3.2 Boehringer Ingelheim GmbH Product Introduction, Application and Specification
        • 8.3.3 Boehringer Ingelheim GmbH LATAM Adalimumab Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.3.4 Main Business and Markets Served
      • 8.4 Eisai Co., Ltd.
        • 8.4.1 Eisai Co., Ltd. LATAM Adalimumab Production Sites and Area Served
        • 8.4.2 Eisai Co., Ltd. Product Introduction, Application and Specification
        • 8.4.3 Eisai Co., Ltd. LATAM Adalimumab Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.4.4 Main Business and Markets Served
      • 8.5 Mylan N.V.
        • 8.5.1 Mylan N.V. LATAM Adalimumab Production Sites and Area Served
        • 8.5.2 Mylan N.V. Product Introduction, Application and Specification
        • 8.5.3 Mylan N.V. LATAM Adalimumab Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.5.4 Main Business and Markets Served
      • 8.6 Novartis AG
        • 8.6.1 Novartis AG LATAM Adalimumab Production Sites and Area Served
        • 8.6.2 Novartis AG Product Introduction, Application and Specification
        • 8.6.3 Novartis AG LATAM Adalimumab Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.6.4 Main Business and Markets Served
      • 8.7 Pfizer, Inc.
        • 8.7.1 Pfizer, Inc. LATAM Adalimumab Production Sites and Area Served
        • 8.7.2 Pfizer, Inc. Product Introduction, Application and Specification
        • 8.7.3 Pfizer, Inc. LATAM Adalimumab Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.7.4 Main Business and Markets Served

      9 Development Trend of Analysis of LATAM Adalimumab Market

      • 9.1 Global LATAM Adalimumab Market Trend Analysis
        • 9.1.1 Global LATAM Adalimumab Market Size (Volume and Value) Forecast 2019-2025
      • 9.2 LATAM Adalimumab Regional Market Trend
        • 9.2.1 North America LATAM Adalimumab Forecast 2019-2025
        • 9.2.2 Europe LATAM Adalimumab Forecast 2019-2025
        • 9.2.3 China LATAM Adalimumab Forecast 2019-2025
        • 9.2.4 Japan LATAM Adalimumab Forecast 2019-2025
        • 9.2.5 Southeast Asia LATAM Adalimumab Forecast 2019-2025
        • 9.2.6 India LATAM Adalimumab Forecast 2019-2025
      • 9.3 LATAM Adalimumab Market Trend (Product Type)
      • 9.4 LATAM Adalimumab Market Trend (Application)
      • 10.1 Marketing Channel
        • 10.1.1 Direct Marketing
        • 10.1.2 Indirect Marketing
      • 10.3 LATAM Adalimumab Customers

      11 Market Dynamics

      • 11.1 Market Trends
      • 11.2 Opportunities
      • 11.3 Market Drivers
      • 11.4 Challenges
      • 11.5 Influence Factors

      12 Conclusion

        13 Appendix

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        Adalimumab was first approved in the U.S. for the treatment of aforementioned medical conditions. Currently, this is marketed in more than 60 countries. However, owing to the biologic nature of the drug, it results in high cost and low accessibility in emerging economies such as LATAM and Asia Pacific. On the other hand, with the probable entry of the adalimumab biosimilars post the patent expiry the low costs up to less than 25% to 35% of the originator drugs will boost the uptake and prescription of adalimumab for the treatment of above mentioned medical conditions.
        Consistent technological sophistications in development of biosimilar followed by increasing incidence and prevalence of various medical conditions have rendered encouraging growth opportunities for various biological drugs and other innovative biopharmaceuticals. The LATAM adalimumab market by application has been categorized on the basis of the usage of adalimumab for treatment of various medical conditions.

        The global LATAM Adalimumab market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
        This report focuses on LATAM Adalimumab volume and value at global level, regional level and company level. From a global perspective, this report represents overall LATAM Adalimumab market size by analyzing historical data and future prospect.
        Regionally, this report categorizes the production, apparent consumption, export and import of LATAM Adalimumab in North America, Europe, China, Japan, Southeast Asia and India.
        For each manufacturer covered, this report analyzes their LATAM Adalimumab manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

        The following manufacturers are covered:
        AbbVie, Inc.
        Amgen, Inc.
        Boehringer Ingelheim GmbH
        Eisai Co., Ltd.
        Mylan N.V.
        Novartis AG
        Pfizer, Inc.
        ...

        Segment by Regions
        North America
        Europe
        China
        Japan
        Southeast Asia
        India

        Segment by Type
        Oral Type
        Injection Type

        Segment by Application
        Rheumatoid Arthritis
        Psoriasis
        Crohn’s Disease
        Ulcerative Colitis
        Others

        Buy now